​
​

Reneo Pharmaceuticals Stock (NASDAQ:RPHM)

ForecastRevenueOwnershipFinancialsChart
Reneo Pharmaceuticals by TradingView

Previous Close

$1.73

52W Range

$1.68 - $82.90

50D Avg

$14.92

200D Avg

$16.09

Market Cap

$60.84M

Avg Vol (3M)

$17.98K

Beta

0.22

Div Yield

-

RPHM Company Profile

Reneo Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the development of therapies for patients with rare genetic mitochondrial diseases. It develops REN001, a selective peroxisome proliferator-activated receptor delta agonist, which is in Phase IIb clinical trial in patients with primary mitochondrial myopathies, as well as in Phase 1b clinical trial in patients with long-chain fatty acid oxidation disorders and glycogen storage disease type V. Reneo Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in San Diego, California.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

8

IPO Date

Apr 08, 2021

Website

RPHM Performance

RPHM Financial Summary

Dec 23Dec 22Dec 21
Revenue---
Operating Income$-83.08M$-53.85M$-39.82M
Net Income$-77.39M$-50.06M$-39.77M
EBITDA$-82.55M$-53.76M$-39.77M
Basic EPS$-2.52$-2.04$-2.19
Diluted EPS$-2.52$-2.04$-2.19

Fiscal year ends in Dec 23 | Currency in USD

Peer Comparison

TickerCompany
DNAGinkgo Bioworks Holdings, Inc.
CNSPCNS Pharmaceuticals, Inc.
ADPTAdaptive Biotechnologies Corporation
CGEMCullinan Oncology, Inc.
DBTXDecibel Therapeutics, Inc.
APLSApellis Pharmaceuticals, Inc.
EWTXEdgewise Therapeutics, Inc.
PRMEPrime Medicine, Inc.
LEGNLegend Biotech Corporation
AVROAVROBIO, Inc.
KRONKronos Bio, Inc.
VIRVir Biotechnology, Inc.
CCCCC4 Therapeutics, Inc.
IMMXImmix Biopharma, Inc.
SMMTSummit Therapeutics Inc.
RPRXRoyalty Pharma plc
HOWLWerewolf Therapeutics, Inc.
NKTXNkarta, Inc.
OCEAOcean Biomedical, Inc.
HEPAHepion Pharmaceuticals, Inc.
KZRKezar Life Sciences, Inc.
CELCCelcuity Inc.